Malcolm A Smith

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program
    Malcolm A Smith
    Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland 20892, USA
    Pediatr Blood Cancer 57:268-74. 2011
  2. ncbi request reprint Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program
    Peter J Houghton
    St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Pediatr Blood Cancer 50:799-805. 2008
  3. pmc Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma
    Malcolm A Smith
    Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland 20892, USA
    Pediatr Blood Cancer 59:753-5. 2012
  4. pmc Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program
    Malcolm A Smith
    Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland 20892, USA
    Pediatr Blood Cancer 59:246-53. 2012
  5. ncbi request reprint Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute
    M A Smith
    Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 15:2736-43. 1997
  6. ncbi request reprint An overview of progress in childhood cancer survival
    Malcolm Smith
    Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, MD 20892, USA
    J Pediatr Oncol Nurs 21:160-4. 2004
  7. ncbi request reprint Commentary on "European collaboration in trials of new agents for children with cancer" by Ablett et al
    Malcolm A Smith
    Cancer Therapy Evaluation Program, NCI 6130, Executive Boulevard Room 7025 Bethesda, MD 20892, USA
    Eur J Cancer 40:1893-5. 2004
  8. ncbi request reprint Double trouble: cancer in twins
    Malcolm Smith
    Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland 20892, USA
    Pediatr Blood Cancer 46:412-3. 2006
  9. doi request reprint Update on developmental therapeutics for acute lymphoblastic leukemia
    Malcolm A Smith
    Cancer Therapy Evaluation Program, National Cancer Institute, 6130 Executive Boulevard, Room 7025, Bethesda, MD 20892, USA
    Curr Hematol Malig Rep 4:175-82. 2009
  10. ncbi request reprint SK-NEP-1 and Rh1 are Ewing family tumor lines
    Malcolm A Smith
    Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA
    Pediatr Blood Cancer 50:703-6. 2008

Detail Information

Publications42

  1. pmc Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program
    Malcolm A Smith
    Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland 20892, USA
    Pediatr Blood Cancer 57:268-74. 2011
    ..The activity of PG11047 was evaluated against the PPTP's in vitro and in vivo panels...
  2. ncbi request reprint Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program
    Peter J Houghton
    St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Pediatr Blood Cancer 50:799-805. 2008
    ..Here we report the activity of rapamycin against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program (PPTP)...
  3. pmc Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma
    Malcolm A Smith
    Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland 20892, USA
    Pediatr Blood Cancer 59:753-5. 2012
    ..Arsenic trioxide did not induce significant differences in EFS distribution compared to control in any of the Ewing sarcoma xenografts studied, and no objective responses were observed...
  4. pmc Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program
    Malcolm A Smith
    Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland 20892, USA
    Pediatr Blood Cancer 59:246-53. 2012
    ..NAE is an essential component of the NEDD8 conjugation pathway, controlling the activity of a subset of ubiquitin-proteasome system (UPS) E3 ligases, multiprotein complexes that transfer ubiquitin molecules to substrate proteins...
  5. ncbi request reprint Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute
    M A Smith
    Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 15:2736-43. 1997
    ..To describe the rationale for independent data monitoring committees (DMCs) for National Cancer Institute (NCI)-sponsored phase III cooperative group clinical trials...
  6. ncbi request reprint An overview of progress in childhood cancer survival
    Malcolm Smith
    Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, MD 20892, USA
    J Pediatr Oncol Nurs 21:160-4. 2004
    ..The experts present at the work group, Moving the Research Agenda Forward for Children With Cancer, offered several possibilities for utilizing CCSS data in expanding research opportunities concerned with cancer survivorship...
  7. ncbi request reprint Commentary on "European collaboration in trials of new agents for children with cancer" by Ablett et al
    Malcolm A Smith
    Cancer Therapy Evaluation Program, NCI 6130, Executive Boulevard Room 7025 Bethesda, MD 20892, USA
    Eur J Cancer 40:1893-5. 2004
    ....
  8. ncbi request reprint Double trouble: cancer in twins
    Malcolm Smith
    Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland 20892, USA
    Pediatr Blood Cancer 46:412-3. 2006
  9. doi request reprint Update on developmental therapeutics for acute lymphoblastic leukemia
    Malcolm A Smith
    Cancer Therapy Evaluation Program, National Cancer Institute, 6130 Executive Boulevard, Room 7025, Bethesda, MD 20892, USA
    Curr Hematol Malig Rep 4:175-82. 2009
    ....
  10. ncbi request reprint SK-NEP-1 and Rh1 are Ewing family tumor lines
    Malcolm A Smith
    Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA
    Pediatr Blood Cancer 50:703-6. 2008
    ..These examples illustrate the importance of molecularly characterizing pediatric preclinical models used for testing new agents...
  11. ncbi request reprint Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins
    M A Smith
    National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 17:569-77. 1999
    ..The Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) has developed a monitoring plan to obtain reliable estimates of the risk of secondary leukemia after epipodophyllotoxin treatment...
  12. ncbi request reprint Trends in reported incidence of primary malignant brain tumors in children in the United States
    M A Smith
    Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA
    J Natl Cancer Inst 90:1269-77. 1998
    ....
  13. ncbi request reprint Conduct of phase I trials in children with cancer
    M Smith
    Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 16:966-78. 1998
    ..Considerations used in prioritizing agents include activity in xenograft models, novel mechanism of action, favorable drug-resistance profile, and activity observed in adult trials of the agent...
  14. doi request reprint Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program
    Malcolm A Smith
    Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland, USA
    Pediatr Blood Cancer 59:329-32. 2012
    ..Objective responses were observed in 4 of 37 solid tumor xenografts, and 2 of 7 ALL xenografts achieved PR or CR. Responses were noted in xenografts with both mutant and wild-type p53...
  15. pmc Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program
    Malcolm A Smith
    Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland 20892, USA
    Pediatr Blood Cancer 54:307-10. 2010
    ..Mapatumumab induced significant differences in event-free survival distribution compared to controls in 9 of 37 evaluable solid tumor xenografts tested, but in none of the 8 ALL xenografts...
  16. doi request reprint Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program
    Malcolm A Smith
    Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland
    Pediatr Blood Cancer 51:34-41. 2008
    ..Alvespimycin (17-DMAG, KOS-1022), a potent small-molecule inhibitor of the protein chaperone Hsp90, is being developed as an anticancer agent because of the multiple Hsp90 client proteins involved in cancer cell growth and survival...
  17. ncbi request reprint Design issues of randomized phase II trials and a proposal for phase II screening trials
    Lawrence V Rubinstein
    Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA
    J Clin Oncol 23:7199-206. 2005
    ....
  18. ncbi request reprint Clinical trials referral resource. Current clinical trials of imatinib mesylate
    Anthony J Murgo
    National Cancer Institute, Bethesda, MD, USA
    Oncology (Williston Park) 17:513, 518, 521 passim. 2003
  19. ncbi request reprint Tissue collection for correlative studies in childhood cancer clinical trials: ethical considerations and special imperatives
    Barry D Anderson
    National Cancer Institute, Cancer Therapy Evaluation Program, Rockville, MD 20892 7436, USA
    J Clin Oncol 22:4846-50. 2004
    ....
  20. pmc microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies
    Jun S Wei
    Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, Gaithersburg, Maryland 20877, USA
    Clin Cancer Res 15:5560-8. 2009
    ..We therefore have performed expression profiles on a panel of pediatric tumors to identify cancer-specific microRNAs. We also investigated if microRNAs are coregulated with their host gene...
  21. ncbi request reprint Clinical trials referral resource. Current clinical trials of molecularly targeted agents in children with cancer
    Malcolm A Smith
    National Cancer Institute, USA
    Oncology (Williston Park) 16:328, 331-3, 338 passim. 2002
  22. pmc Outcomes for children and adolescents with cancer: challenges for the twenty-first century
    Malcolm A Smith
    Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 28:2625-34. 2010
    ..This report provides an overview of current childhood cancer statistics to facilitate analysis of the impact of past research discoveries on outcome and provide essential information for prioritizing future research directions...
  23. pmc A proposal regarding reporting of in vitro testing results
    Malcolm A Smith
    Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 19:2828-33. 2013
    ....
  24. pmc The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia
    Hernan Carol
    Children s Cancer Institute Australia for Medical Research, University of New South Wales, Sydney, Australia
    Clin Cancer Res 19:1795-805. 2013
    ..In this study, we evaluated the efficacy of SAR3419, an antibody-drug conjugate of the maytansinoid DM4 and a humanized anti-CD19 antibody, against B-cell precursor (BCP)-ALL and infant mixed lineage leukemia (MLL) xenografts...
  25. ncbi request reprint Clinical trials refferal resource. Current clinical trials of new agents and novel therapies in pediatric leukemia and lymphoma
    Malcolm A Smith
    National Cancer Institute, Bethesda, MD, USA
    Oncology (Williston Park) 17:1377, 1380, 1383-4. 2003
  26. ncbi request reprint Clinical trials referral resource. Current clinical trials of molecularly targeted agents in children with cancer, Part 2
    Malcolm A Smith
    National Cancer Institute, USA
    Oncology (Williston Park) 16:474, 479-80, 483-4 passim. 2002
  27. ncbi request reprint Preliminary data release for randomized clinical trials of noninferiority: a new proposal
    Edward L Korn
    Biometric Research Branch and Clinical Investigations Branch, Division of Cancer Treatment and Diagnosis, EPN 8128, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 23:5831-6. 2005
    ..Examples are given demonstrating how the proposal would work, along with a discussion of possible objections to the proposal...
  28. ncbi request reprint Initial testing of cisplatin by the pediatric preclinical testing program
    Mimi Tajbakhsh
    Children s Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia
    Pediatr Blood Cancer 50:992-1000. 2008
    ..Cisplatin is one of the most widely used drugs for the treatment of solid tumors in adults and children. Here, we report the activity of cisplatin against the PPTP panels of childhood cancer xenografts...
  29. ncbi request reprint Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project
    Leslie L Robison
    Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota
    Med Pediatr Oncol 38:229-39. 2002
    ..To facilitate such research, a multi-institutional consortium established the Childhood Cancer Survivor Study (CCSS), a large, diverse, and well-characterized cohort of 5-year survivors of childhood and adolescent cancer...
  30. doi request reprint Molecular characterization of the pediatric preclinical testing panel
    Geoffrey Neale
    Hartwell Center of Bioinformatics and Biotechnology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Clin Cancer Res 14:4572-83. 2008
    ..Identifying novel therapeutic agents for the treatment of childhood cancers requires preclinical models that recapitulate the molecular characteristics of their respective clinical histotypes...
  31. ncbi request reprint Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis
    Craig C Whiteford
    Oncogenomics Section, Comparative Oncology Program, and Cell and Molecular Biology Section, Pediatric Oncology Branch
    Cancer Res 67:32-40. 2007
    ..The database will facilitate the identification of tumor markers predictive of response to tested agents as well as the discovery of new molecular targets...
  32. doi request reprint Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program
    John M Maris
    Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine and Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania, USA
    Pediatr Blood Cancer 51:42-8. 2008
    ..Sunitinib is an orally bioavailable, multi-targeted tyrosine kinase inhibitor with selectivity for PDGF receptors, VEGF receptors, FLT3, and KIT...
  33. ncbi request reprint Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Larry V Rubinstein
    J Natl Cancer Inst 99:1422-3. 2007
  34. pmc Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program
    Stephen T Keir
    Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina 27710, USA
    Pediatr Blood Cancer 51:439-41. 2008
    ..VNP4010M antitumor activity was observed only in the absence of MGMT expression, with resistance to VNP4010M seen even with low MGMT expression...
  35. ncbi request reprint Testing of new agents in childhood cancer preclinical models: meeting summary
    Peter J Houghton
    St Jude Children s Research Hospital, Memphis, Tennessee 38101, USA
    Clin Cancer Res 8:3646-57. 2002
    ..This report is a synthesis of the workshop's presentations and discussions...
  36. ncbi request reprint Initial testing of dasatinib by the pediatric preclinical testing program
    E Anders Kolb
    The Children s Hospital at Montefiore, Bronx, New York, USA
    Pediatr Blood Cancer 50:1198-206. 2008
    ..Dasatinib, a dual inhibitor of the src and abl tyrosine kinases, was recently approved by the Federal Drug Administration for the treatment of imatinib mesylate-resistant chronic myeloid leukemia...
  37. ncbi request reprint Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program
    John M Maris
    Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine and Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania, USA
    Pediatr Blood Cancer 50:581-7. 2008
    ..This study was designed to screen for antitumor activity of AZD2171 against the in vitro and in vivo childhood cancer preclinical models of the Pediatric Preclinical Testing Program (PPTP)...
  38. ncbi request reprint A window on reality?
    Malcolm A Smith
    J Clin Oncol 22:1360-2. 2004
  39. ncbi request reprint Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program
    Richard Lock
    Children s Cancer Institute Australia for Medical Research, Randwick, NSW, Australia
    Pediatr Blood Cancer 50:1181-9. 2008
    ....
  40. doi request reprint Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program
    E Anders Kolb
    Albert Einstein College of Medicine, The Children s Hospital at Montefiore, Bronx, New York, USA
    Pediatr Blood Cancer 50:1190-7. 2008
    ..The activity of SCH 717454 was evaluated against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program (PPTP)...
  41. ncbi request reprint Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program
    Peter J Houghton
    St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Pediatr Blood Cancer 50:37-45. 2008
    ..The purpose of the current study was to evaluate the antitumor activity of bortezomib against the in vitro and in vivo childhood cancer preclinical models of the Pediatric Preclinical Testing Program (PPTP)...
  42. ncbi request reprint The pediatric preclinical testing program: description of models and early testing results
    Peter J Houghton
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Pediatr Blood Cancer 49:928-40. 2007
    ..Here, we describe the characteristics of the in vivo tumor panels and report results for the in vivo evaluation of two standard agents, vincristine and cyclophosphamide...